Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two-part study to evaluate safety, tolerability, and pharmacokinetics of single escalating oral doses of GSK945237 and the effect of food on single oral doses of GSK945237 in healthy adult subjects.

Next Previous
X
Search
Trial Profile

A two-part study to evaluate safety, tolerability, and pharmacokinetics of single escalating oral doses of GSK945237 and the effect of food on single oral doses of GSK945237 in healthy adult subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 945237 (Primary)
  • Indications Bacterial infections
  • Focus Adverse reactions

    • Most Recent Events

    • 13 May 2011 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2008 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 28 Aug 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top